Table 4.
Adjusted multivariate survival analyses
| Comparison of staining | p53 | SSTR-2a | CgA | |||
|---|---|---|---|---|---|---|
| HR (CI) | p | HR (CI) | p | HR (CI) | p | |
| All 3 categories without dichotomisation | 1.26 (0.99–1.60) | 0.07 | 0.91 (0.72–1.15) | 0.41 | 0.89 (0.69–1.15) | 0.38 |
| A: Neg (vs. het-pos) | 1.88 (1.01–3.49) | 0.05* | 1.18 (0.61–2.29) | 0.63 | 2.11 (1.15–3.88) | 0.02* |
| B: Het-pos (vs. pos) | 0.33 (0.19–0.60) | < 0.001* | 1.18 (0.54–2.58) | 0.68 | 1.13 (0.68–1.87) | 0.63 |
| C: Pos (vs. neg) | 1.30 (0.83–2.04) | 0.25 | 0.84 (0.52–1.35) | 0.47 | 0.78 (0.47–1.30) | 0.34 |
| D: Neg (vs. het-pos + pos) | 1.03 (0.67–1.58) | 0.88 | 1.19 (0.78–1.82) | 0.41 | 1.39 (0.89–2.18) | 0.15 |
| E: Het-pos (vs. neg + pos) | 0.45 (0.27–0.75) | 0.002* | 1.08 (0.57–2.04) | 0.82 | 1.31 (0.84–2.04) | 0.23 |
| F: Pos (vs. het-pos + neg) | 1.85 (1.24–2.76) | 0.003* | 0.84 (0.53–1.34) | 0.47 | 0.97 (0.65–1.47) | 0.89 |
Adjusted for age (> 65 years), gender, grade of differentiation (well- vs. poorly differentiated), primary tumour (pancreas vs. other primary tumours), tumour burden (locoregional disease vs. disseminated), performance status (PS > 2), and treatment (surgery or chemotherapy). The immune-staining outside the parenthesis in the column “Comparison of staining” indicated which score the HR relates to. *Indicates significant p-values < 0.05. Unadjusted HR (CI) and p-values are presented in Fig. 4, and were significant for p53 in the A and B comparison in the univariate analyses